A pat­ent dis­pute between GSK sub­si­di­ary ViiV Health­care and Colom­bian reg­u­lat­ors is not cur­rently before the Inter­na­tional Centre for Set­tle­ment of Invest­ment Dis­putes in Wash­ing­ton ...

ViiV Healthcare 的新型长效注射剂Cabenuva（cabotegravir 和 rilpivirine）每隔一个月给药一次，可抑制 HIV 三年，而且还在不断增加。含有多替拉韦的两种药物 ...

J&J and ViiV – majority-owned by GlaxoSmithKline – hope that the streamlined process will help boost take-up of Cabenuva, which became the first long-acting alternative to daily ART last year.

GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi as ...

ViiV did not say how it acquired the priority review voucher, but last year it used the same strategy to hasten the FDA’s review of another single-tablet combination HIV therapy of Tivicay ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...

From December 22 to January 2, people on Grindr across the globe can experience Roam, a popular new feature, free of charge.

Garges, M.D., Chief Medical Officer, at ViiV Healthcare, said: “We know taking fewer medicines is an important consideration for many in the HIV community, and these new data continue to ...